NASDAQ Framework: Apellis Pharmaceuticals Inc.
1: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of... View Source2: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. View Source3: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. View Source
Apellis Pharmaceuticals, Inc., founded in 2009 and headquartered in Waltham, MA, is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutic compounds aimed at treating diseases with high unmet needs through the inhibition of the complement system 456. The company's approved treatments include SYFOVRE for geographic atrophy secondary to age-related macular degeneration and EMPAVELI for paroxysmal nocturnal hemoglobinuria, among other indications 78. Apellis has achieved significant milestones in the challenging field of geographic atrophy treatments, positioning itself as a leader with a competitive edge in this complex therapeutic space 9.
4: Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA. View Source5: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. View Source6: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. View Source7: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of... View Source8: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. View Source9: Brian Skorney has given his Buy rating due to a combination of factors impacting Apellis Pharmaceuticals. A key element behind this positive outlook is the recent clinical failure of a competing drug from Roche, which was anticipated to be a direct competitor to Apellis’s offerings in the geographic atrophy (GA) market. With Roche’s asset now discontinued, a potential risk to Apellis’s market position has been effectively removed, solidifying its standing in the treatment landscape for GA. Moreover, the discontinuation underscores the difficulty of developing successful treatments for GA, a field where Apellis has already achieved significant milestones. Additionally, the market for GA treatments is noted to be particularly challenging, marked by numerous failures in both early and advanced stages of drug development. Apellis’s product, Syfovre, stands as one of the few approved treatments in this area, emphasizing the company’s competitive edge. Given the scarcity of effective therapies and the high barrier to entry due to the complexity of the disease, Apellis is well-positioned to maintain and potentially expand its market share. Skorney’s Buy rating reflects the reduced competitive pressure and Apellis’s established role as a leader in a difficult-to-navigate therapeutic space. View Source
UNKNOWN
The provided facts do not specify whether the founders of Apellis Pharmaceuticals Inc. are still leading the company or are heavily involved in its current operations. While it is mentioned that the company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels 10, there is no information about their current roles or involvement.
The provided facts do not specify whether the founders of Apellis Pharmaceuticals Inc. are still leading the company or are heavily involved in its current operations. While it is mentioned that the company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels 10, there is no information about their current roles or involvement.
10: Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA. View Source
MEDIUM RISK
Apellis Pharmaceuticals Inc. has shown solid revenue growth and a strong market position, particularly with its product Syfovre for geographic atrophy, which faces reduced competitive pressure due to a competitor's clinical failure 1112. However, the company has a net margin of -38.55% and a return on equity of -28.8%, indicating ongoing financial challenges 1314. Additionally, the company is facing legal scrutiny and potential risks related to the commercial adoption of its products 1516. While its debt-to-equity ratio is below average, suggesting prudent debt management 17, the combination of profitability issues and legal challenges places Apellis in a medium risk category.
Apellis Pharmaceuticals Inc. has shown solid revenue growth and a strong market position, particularly with its product Syfovre for geographic atrophy, which faces reduced competitive pressure due to a competitor's clinical failure 1112. However, the company has a net margin of -38.55% and a return on equity of -28.8%, indicating ongoing financial challenges 1314. Additionally, the company is facing legal scrutiny and potential risks related to the commercial adoption of its products 1516. While its debt-to-equity ratio is below average, suggesting prudent debt management 17, the combination of profitability issues and legal challenges places Apellis in a medium risk category.
11: Brian Skorney has given his Buy rating due to a combination of factors impacting Apellis Pharmaceuticals. A key element behind this positive outlook is the recent clinical failure of a competing drug from Roche, which was anticipated to be a direct competitor to Apellis’s offerings in the geographic atrophy (GA) market. With Roche’s asset now discontinued, a potential risk to Apellis’s market position has been effectively removed, solidifying its standing in the treatment landscape for GA. Moreover, the discontinuation underscores the difficulty of developing successful treatments for GA, a field where Apellis has already achieved significant milestones. Additionally, the market for GA treatments is noted to be particularly challenging, marked by numerous failures in both early and advanced stages of drug development. Apellis’s product, Syfovre, stands as one of the few approved treatments in this area, emphasizing the company’s competitive edge. Given the scarcity of effective therapies and the high barrier to entry due to the complexity of the disease, Apellis is well-positioned to maintain and potentially expand its market share. Skorney’s Buy rating reflects the reduced competitive pressure and Apellis’s established role as a leader in a difficult-to-navigate therapeutic space. View Source12: Revenue Growth: Apellis Pharmaceuticals displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 284.26%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers. View Source13: Net Margin: Apellis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -38.55%, the company demonstrates strong profitability and effective cost management. View Source14: Return on Equity (ROE): Apellis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -28.8%, the company may face hurdles in achieving optimal financial performance. View Source15: (MENAFN- PR Newswire) NEW YORK, July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS ) breached their fiduciary duties to shareholders. View Source16: According to a federal securities lawsuit, Apellis insiders caused the company to misrepresent or fail to disclose that (1) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, statements about the company's business, operations, and prospects lacked a reasonable basis. View Source17: Debt Management: With a below-average debt-to-equity ratio of 0.41, Apellis Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management. View Source
NO
There is no evidence in the provided facts indicating that Apellis Pharmaceuticals Inc. is launching any new product offerings. The information focuses on existing products like SYFOVRE and EMPAVELI, as well as ongoing clinical trials and collaborations, but does not mention any new product launches 1819.
There is no evidence in the provided facts indicating that Apellis Pharmaceuticals Inc. is launching any new product offerings. The information focuses on existing products like SYFOVRE and EMPAVELI, as well as ongoing clinical trials and collaborations, but does not mention any new product launches 1819.
18: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of... View Source19: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. View Source
Apellis Pharmaceuticals Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on solidifying its leadership in the treatment of geographic atrophy (GA) and expanding its therapeutic offerings through ongoing clinical trials and strategic collaborations. The company aims to leverage its competitive edge with SYFOVRE, one of the few approved treatments for GA, while addressing the high barriers to entry in this challenging market 202122. Additionally, Apellis is advancing its pipeline with APL-3007, a small interfering RNA (siRNA) in Phase 1 clinical trials, and an oral complement inhibitor in preclinical development 23. The company also collaborates with Beam Therapeutics to explore new treatments for complement-driven diseases, further enhancing its innovative capabilities 24.
20: Brian Skorney has given his Buy rating due to a combination of factors impacting Apellis Pharmaceuticals. A key element behind this positive outlook is the recent clinical failure of a competing drug from Roche, which was anticipated to be a direct competitor to Apellis’s offerings in the geographic atrophy (GA) market. With Roche’s asset now discontinued, a potential risk to Apellis’s market position has been effectively removed, solidifying its standing in the treatment landscape for GA. Moreover, the discontinuation underscores the difficulty of developing successful treatments for GA, a field where Apellis has already achieved significant milestones. Additionally, the market for GA treatments is noted to be particularly challenging, marked by numerous failures in both early and advanced stages of drug development. Apellis’s product, Syfovre, stands as one of the few approved treatments in this area, emphasizing the company’s competitive edge. Given the scarcity of effective therapies and the high barrier to entry due to the complexity of the disease, Apellis is well-positioned to maintain and potentially expand its market share. Skorney’s Buy rating reflects the reduced competitive pressure and Apellis’s established role as a leader in a difficult-to-navigate therapeutic space. View Source21: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of... View Source22: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. View Source23: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. View Source24: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. View Source